To verify this, we treated NSCLC cell lines A549 and H520 with the clinical anti‐PD‐L1 monoclonal antibody Atezolizumab alone or in combination with peripheral blood mononuclear cells (PBMCs), and subsequently detected changes in HLA‐G levels. Here, HLA-G is linked to non-small cell lung carcinoma.